To study the effect of spironolactone on dietary electrolyte supplementation, pulmonary function, and electrolyte balance in premature infants with chronic lung disease.
Chronic lung disease may develop in premature infants who require mechanical ventilation and prolonged high concentrations of inspired oxygen for the management of respiratory distress syndrome. This disease affects from 5% to 20% of premature newborn infants who receive intermittent positive pressure ventilation. 1 Long-term diuretic therapy is an important component of the care received by premature infants with chronic lung disease. 2 The combination of oral chlorothiazide and spironolactone has been shown to decrease mean airway resistance and increase airway conductance and compliance in premature infants diagnosed with bronchopulmonary dysplasia. 3 The use of Aldactazide (a 1:1 mixture of spironolactone and hydrochlorothiazide), however, did not improve pulmonary mechanics or oxygenation despite the occurrence of a diuresis. 4 Further, potassium depletion is a known complication of diuretic administration. A common medical practice among neonatologists is to add spironolactone to the diuretic regimen to decrease the degree of hypokalemia and hyperkaliuria. 5 Despite the addition of this potassiumsparing diuretic, many neonates still require dietary supplementation with potassium chloride and/or sodium chloride. However, the additive effect of spironolactone to thiazide therapy on pulmonary mechanics and electrolyte balance has not been studied. Because the distal convoluted tubule in the premature infant is less responsive to the effects of aldosterone than in older children, 6 the administration of spironolactone, the synthetic antagonist of aldosterone, may not have an important role in the maintenance of potassium balance or in the improvement of pulmonary mechanics in low birth weight infants with chronic lung disease.
This double-blind, placebo controlled randomized study was performed to determine whether the addition of spironolactone to a chlorothiazide regimen would decrease the need for electrolyte supplementation. The secondary aim was to determine whether spironolactone improved pulmonary mechanics and electrolyte balance in premature infants with chronic lung disease.
METHODS

Study Population
This study was approved by the Research Review Committee of Pennsylvania Hospital. A total of 33 infants with a postconceptional age of 26 -36 weeks were enrolled. An equal number of infants with an age of Յ32 weeks and Ͼ32 weeks, respectively, were randomized to each group. Informed consent was obtained from one or both parents by one of the principal investigators after the nature of the study was explained. The eligibility criteria were: the presence of chronic lung disease (defined by oxygen dependency beyond 28 days of life coexistent with characteristic radiographic abnormalities), the establish- Original Article
ment of enteral feeding, and the decision by the attending physician to prescribe oral diuretics. Infants were excluded from the study if at the time of enrollment they were receiving the early portion of a course of dexamethasone (0.1 to 0.5 mg/kg per day), hyperalimentation, intravenous fluids, or furosemide, or if renal anomalies were known.
Study Protocol
A total of 33 infants were enrolled in the study and randomized to a spironolactone or a placebo group. Infants in the spironolactone group (n ϭ 17) received the combination of chlorothiazide (20 mg/kg per dose orally twice a day) and spironolactone (1.5 mg/kg per dose orally twice a day). Infants in the placebo group (n ϭ 16) received the same dose of chlorothiazide and a placebo. To mask the identities of either spironolactone or placebo, the order was written for "chlorothiazide" and "study medication," respectively. The placebo and spironolactone doses were prepared in identical unit aliquots with equal volumes and colors of the solution. Only the pharmacists were aware of the randomization schedule. Pulmonary function testing, serum electrolyte determinations obtained from heel stick capillary samples, fluid intake and output, oxygen saturations, and the need for and the quantity of dietary sodium chloride (NaCl) or potassium chloride (KCl) supplementation were monitored at the following intervals: day 0 (baseline) and day 14 of the 2-week study period. NaCl supplementation was prescribed for serum concentrations of sodium of Ͻ130 mEq/liter. KCl was given for potassium or chloride serum concentrations of Ͻ3.5 mEq/liter and 95 mEq/liter, respectively. Baseline studies were performed at 3 to 5 days after the last dose of furosemide to allow for adequate renal clearance, 7 given the plasma half-life of 24 hours. 8 At the baseline point of the study, four infants in the spironolactone group and two infants in the placebo group were intubated and required mechanical ventilation. Continuous positive airway pressure delivered through nasal prongs was required by three infants in the spironolactone group and one infant in the placebo group. At the 14-day endpoint, mechanical ventilation was required by one infant in the spironolactone group and two infants in the placebo group, nasal continuous positive airway pressure was administered to two infants in the spironolactone group, but was not given to any infants in the placebo group. All of the infants received methyl xanthine therapy during the study. A total of 12 infants in each group received a low, tapering dose of dexamethasone during the study period. Total fluid intake with commercial infant formula (Similac Special Care, Ross Laboratories, Columbus, OH) or breast milk was similar in both groups. Two infants in the spironolactone group were fed Pregestimil (Mead-Johnson, Evanston, IL). A similar proportion of infants in each group were fed human milk or formula, respectively.
Pulmonary Function Measurement
Pulmonary mechanics were determined in unsedated patients on days 0 and 14 of the study. The neonates were placed supine with their head in a neutral position. Data were obtained while the unsedated infant was resting quietly and breathing spontaneously before feeding.
For infants on continuous positive airway pressure, the nasal prongs were temporarily removed, and a face mask was applied. Simultaneous signals of airflow, tidal volume, and transpulmonary pressure were relayed to a custom-designed software program for data analysis and graphic display. Airflow was measured by a pneumotachometer (Fleish model 00, OEM Medical, Richmond, VA) attached to a face mask or endotracheal tube. Esophageal pressure was measured with a polyvinyl balloon (Mallinckrodt, Argyle, NY) measuring 0.40 mm in length and 7.5 mm in width containing 0.2 ml of air, placed in the distal esophagus. Transpulmonary pressure was measured by a Celesco differential pressure transducer (model P7, Celesco Transducer Products, Canoga, NY). Simultaneous records of airflow volume and transpulmonary pressure were sampled and recorded at a rate of 75 Hz per channel. Any breaths with artifact in flow or pressure signals, difference in inspiratory and expiratory tidal volume, or a tidal volume of Ͻ0.5 ml were excluded. Values for lung mechanics were calculated from 25 to 45 breaths by least mean squares analysis.
Statistical Analysis
The primary aim of this study was to determine whether there was a difference in the need for dietary electrolyte supplementation between the two groups. A power analysis, performed during the design of the study, was based on the expected requirement for KCl supplementation for infants who received the combination of chlorothiazide and spironolactone (spironolactone group) and those that received chlorothiazide and placebo (placebo group). The two treatments would have been considered to be equivalent with regard to the need for potassium supplementation if the difference between the two groups was not Ͼ25%. A minimum of 15 infants in each group was required to test this hypothesis with 80% power and a significance level of 0.05. Two way t-tests were used to compare each experimental variable.
RESULTS
The baseline data presented in Table 1 show that the two groups were equally randomized according to the entry criteria. There were nostatistically significant differences between the two groups for the fol- lowing baseline measurements: birth weight, gestational age, postconceptional age at the time of study entry, and Apgar score at 5 minutes of life. Although the average weights of the two groups were statistically significant from one another, the difference was not clinically significant. The two groups had similar fraction of inspired oxygen concentration, tidal volume, compliance, and resistance at baseline after 14 days of the study period ( Table 2 ). The total fluid intake in the two groups was similar and ranged from 140 to 160 ml/kg per day. Renal function on day 14, determined by serum creatinine measurements, was not significantly different between the two groups (0.5 Ϯ 0.2 vs 0.5 Ϯ 0.1 mg/dl).
The main determinant in this study was the need for sodium or potassium supplementation in the two groups (Table 3) . A total of 11 infants in the spironolactone group received NaCl, and 9 of them received KCl. In the placebo group, KCl and NaCl were each required by seven infants. Six infants in the spironolactone group did not require any salt supplementation compared with eight infants in the placebo group. Infants in the spironolactone group received 40.6 Ϯ 39.2 mEq/kg of supplemental NaCl during the study period compared with 32.4 Ϯ 42.8 mEq/kg in the placebo group ( p ϭ not significant (NS)). The requirements for KCl in the same groups were 15.2 Ϯ 20.5 mEq/kg and 12.8 Ϯ 15.8 mEq/kg, respectively ( p ϭ NS).
Although the absolute mean value for pulmonary resistance in the spironolactone group was lower than the value in the placebo group on day 14 (Figure 1) , the percent changes from the respective baseline values were not significantly different (5.2% in the spironolactone group versus 14.8% in the placebo group). The percent changes for pulmonary compliance for the same groups were 4.7% and 8.7%, respectively.
DISCUSSION
Infants with bronchopulmonary dysplasia have shown improvements in lung function with diuretic therapy. Acute short-and long-term improvements in airway resistance, conductance, and compliance have been demonstrated with furosemide therapy and with the combination of chlorothiazide and spironolactone. 3,9 -15 Many side effects, however, are associated with the long-term use of diuretics, including electrolyte and mineral imbalance. Supplemental electrolytes consisting of NaCl and KCl are often required to manage the electrolyte imbalance observed in these infants. Spironolactone, a potassium-sparing diuretic, is often added to a regimen consisting of chlorothiazide to avoid the need for KCl supplementation. In our clinical experience, however, many premature infants with chronic lung disease receive electrolyte supplementation despite the use of spironolactone. The primary aim of this study was to determine whether the use of spironolactone in combination with chlorothiazide reduced the need for electrolyte supplementation. Secondary outcome measures were its effect on pulmonary mechanics and electrolyte balance. An overall analysis of diuretic therapy concluded that the benefits of diuretic therapy outweigh the risks associated with their long-term use. 16 However, if the use of spironolactone does not produce its supposed effects, drug-related costs and morbidity may develop without benefiting the patient.
The data presented in this study show that the addition of spironolactone did not mitigate the need to prescribe potassium or sodium salts in this population of infants; secondarily, the combination of chlorothiazide and spironolactone did not result in improved pulmonary mechanics or electrolyte balance compared with the use of chlorothiazide alone. These findings may not be statistically evident from these data, however, because the power analysis was not performed for these secondary outcome measures. Due to the wide SD noted in these measurements, a much larger sample size would be needed to avoid a type 2 statistical error. It is possible that a higher dose of spironolactone and/or a longer duration of treatment may have produced a difference between the two groups for any of the measured factors.
Because both groups were equivalent with regard to the need to supplement with potassium and/or sodium salts under this commonly practiced drug regimen, the efficacy of spironolactone is questionable. Further, the use of this drug results in increased costs related to the drug itself and to its administration, as well as to potential drug-related side effects. Although a description of drug-related toxicities was not a goal of this study, there are many reported side effects associated with the use of spironolactone, including gastrointestinal distress and gynecomastia. 5 Other related side effects may be due to the drug's steroid cell target actions and to an effect on steroid biosynthetic pathways.
The ineffectiveness of spironolactone, a synthetic analog of aldosterone, may be related to the development of the kidney in the premature infant. Renal function in the premature infant born before 34 weeks' gestation is limited for weeks beyond birth, 17 during which time the kidney undergoes many anatomic and physiological changes. The hyponatremia of prematurity may be due to a partial unresponsiveness of the distal nephron to aldosterone. 6 Although serum aldosterone concentrations are high in the neonate, end-organ responsiveness may be altered. The action of aldosterone is to increase the resorption of sodium and the secretion of potassium. Spironolactone, an aldosterone antagonist, is only effective in the presence of aldosterone. 18 The renin-angiotensin-aldosterone system in neonates has been studied extensively. Newborn animals and humans have higher aldosterone concentrations than adults. 19, 20 Preterm infants with a mean gestational age of 31 weeks who did not receive sodium supplementation showed an increase in plasma aldosterone concentration and urinary aldosterone excretion over the first few weeks of life, followed by a decrease over the following 2 weeks. Conversely, no changes in these measurements were observed in infants who received supplemental sodium when compared with full-term newborn infants. 21 Further, excretion of urinary aldosterone is higher in preterm infants than in term infants, corresponding to a low urinary potassium to sodium ratio, suggesting impaired end-organ responsiveness to aldosterone. 22 If the distal tubule is unresponsive to aldosterone either through a decreased number of receptors or diminished ATPase activity, it can be speculated that it may not be responsive to its antagonist either, resulting in an inadequate potassium-sparing effect. In rats, however, it has been shown that there are equal numbers of aldosterone-binding sites in immature and adult animals, suggesting that the impaired response to aldosterone in immature rats is due to events beyond the receptor site. Conversely, any possible potassium-sparing effect of spironolactone may be masked by the greater effect of urinary potassium losses by chlorothiazide. Urinary potassium losses have been shown to be higher when spironolactone is combined with furosemide or chlorothiazide compared with the use of spironolactone as a single agent. 23 In summary, the combination of spironolactone and chlorothiazide did not diminish the need to prescribe potassium salts in this patient population. Furthermore, the use of spironolactone did not offer any additional benefits concerning pulmonary function or electrolyte balance. These data do not support the widespread practice of prescribing spironolactone in this group of premature infants with chronic lung disease. Additional studies could be performed to evaluate the effect of either higher doses of spironolactone or a longer duration of treatment. 
